Avantor, Inc. (AVTR)
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
- Ticker
- AVTR
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Market cap
- $10.47B
- 52-week range
- $7.26 - $17.45
Valuation
- Share price
- $15.47 (close of Nov 6, 2026)
- P/E (TTM)
- 30.94x
- Price to book
- 1.79x
- Price to free cash flow
- 23.85x
- Enterprise value
- $13.69B
- Book value per share
- $8.62
Price performance
| Period | Change |
|---|---|
| 1 day | +2.18% |
| 5 days | -3.61% |
| 1 month | +0.26% |
| 3 months | +17.37% |
| 6 months | +83.51% |
| Year to date | +34.99% |
| 1 year | +36.66% |
| 3 years | -15.33% |
| 5 years | -59.48% |
| All time | +6.69% |
Short interest
- As of
- Oct 15, 2026
- Short % of float
- 6.20%
- Shares short
- 34.65M
- Days to cover
- 4.58
- Change since prior report
- -11.95%
- Source
- FINRA consolidated short interest
Members of Congress who disclosed AVTR trades
Gilbert Ray Cisneros · Lisa McClain
Super investors holding AVTR
Dodge & Cox (Dodge & Cox Funds) · Greenhaven Associates (Greenhaven Associates Inc) · First Pacific Advisors (First Pacific Advisors, LP) · Yacktman Asset Mgmt (Yacktman Asset Management LP) · Mason Hawkins (Southeastern Asset Management) · Robert Olstein (Olstein Capital Management) · Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates)
Profitability and growth
- Return on equity
- -9.53%
- Return on invested capital
- -2.59%
- Return on assets
- -4.50%
- Return on capital employed
- -2.36%
- Gross margin
- 32.65%
- Net margin
- -8.09%
- EBITDA margin
- 2.50%
- Revenue growth
- -3.41%
- Net income growth
- -174.52%
- Free cash flow growth
- -28.47%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 4.19%
- Current ratio
- 1.89x
- Net debt to EBITDA
- 3.59x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- Revenue
- $6.55B
- Cost of revenue
- $4.41B
- Gross profit
- $2.14B
- EBITDA
- $164.00M
- Net income
- -$530.20M
- Earnings per share
- $-0.78
- Interest expense
- $169.80M
- Shares outstanding
- 680.60M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $6.55B | $2.14B | -$530.20M | -$0.78 |
| 2024-12-31 | $6.78B | $2.28B | $711.50M | $1.05 |
| 2023-12-31 | $6.97B | $2.36B | $321.10M | $0.48 |
| 2022-12-31 | $7.51B | $2.60B | $686.50M | $1.02 |
| 2021-12-31 | $7.39B | $2.50B | $572.60M | $0.86 |
| 2020-12-31 | $6.39B | $2.08B | $116.60M | $0.09 |
| 2019-12-31 | $6.04B | $1.92B | $37.80M | -$0.84 |
| 2018-12-31 | $5.86B | $1.82B | -$86.90M | -$2.69 |
| 2017-12-31 | $1.25B | $432.80M | -$112.70M | -$2.75 |
| 2016-12-31 | $691.30M | $319.70M | -$42.40M | - |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 32.65% | -8.09% | -9.53% | -2.59% |
| 2024-12-31 | 33.60% | 10.49% | 11.94% | 9.41% |
| 2023-12-31 | 33.93% | 4.61% | 6.11% | 5.63% |
| 2022-12-31 | 34.65% | 9.14% | 14.14% | 8.67% |
| 2021-12-31 | 33.88% | 7.75% | 13.64% | 6.94% |
| 2020-12-31 | 32.54% | 1.82% | 4.36% | 9.09% |
| 2019-12-31 | 31.80% | 0.63% | 1.54% | 7.06% |
| 2018-12-31 | 31.03% | -1.48% | - | 10.68% |
| 2017-12-31 | 34.70% | -9.03% | - | - |
| 2016-12-31 | 46.25% | -6.13% | - | - |
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-31 | $365.40M | $3.92B |
| 2024-12-31 | $261.90M | $3.23B |
| 2023-12-31 | $262.90M | $5.28B |
| 2022-12-31 | $372.90M | $5.92B |
| 2021-12-31 | $301.70M | $6.98B |
| 2020-12-31 | $286.60M | $4.87B |
| 2019-12-31 | $186.70M | $5.02B |
| 2018-12-31 | $184.70M | $6.78B |
| 2017-12-31 | $185.40M | $7.01B |
| 2016-12-31 | $62.90M | $1.28B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $495.00M | $46.40M |
| 2024-12-31 | $692.00M | $46.80M |
| 2023-12-31 | $723.60M | $40.50M |
| 2022-12-31 | $710.20M | $45.80M |
| 2021-12-31 | $842.50M | $50.70M |
| 2020-12-31 | $868.20M | $44.10M |
| 2019-12-31 | $302.40M | $67.90M |
| 2018-12-31 | $162.80M | $18.40M |
| 2017-12-31 | -$192.70M | $48.20M |
| 2016-12-31 | $43.00M | $98.70M |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-10-28 | Sep 2026 | $0.21 |
| 2026-07-29 | Jun 2026 | $0.19 |
| 2026-04-29 | Mar 2026 | $0.16 |
| 2026-02-11 | Dec 2025 | $0.21 |
| 2025-10-29 | Sep 2025 | $0.23 |
| 2025-08-01 | Jun 2025 | $0.25 |
| 2025-04-25 | Mar 2025 | $0.23 |
| 2025-02-07 | Dec 2024 | $0.25 |
Filings and sources
- Company website
- avantorsciences.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Cooper Companies, Inc. (COO) · Baxter International Inc (BAX) · Align Technology Inc (ALGN) · Solventum Corp (SOLV) · Repligen Corp (RGEN) · West Pharmaceutical Services Inc (WST) · Teleflex Inc (TFX) · Alcon Inc (ALC)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades